JPMorgan Chase & Co. Reduces Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

JPMorgan Chase & Co. lessened its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 19.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,050,122 shares of the company's stock after selling 504,044 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.94% of Hims & Hers Health worth $37,763,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Renaissance Technologies LLC grew its stake in Hims & Hers Health by 113.1% in the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company's stock valued at $121,936,000 after purchasing an additional 3,205,108 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Hims & Hers Health by 34.5% in the 3rd quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company's stock valued at $63,446,000 after buying an additional 883,230 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company's stock worth $79,029,000 after buying an additional 482,177 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund raised its stake in shares of Hims & Hers Health by 164.1% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company's stock worth $10,663,000 after acquiring an additional 328,142 shares in the last quarter. Finally, Carnegie Investment Counsel purchased a new stake in Hims & Hers Health during the third quarter valued at approximately $5,531,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Up 0.7 %

Shares of HIMS stock traded up $0.19 on Monday, hitting $26.82. The company had a trading volume of 9,029,169 shares, compared to its average volume of 8,615,215. The firm has a market cap of $5.86 billion, a P/E ratio of 60.96 and a beta of 1.31. Hims & Hers Health, Inc. has a twelve month low of $8.14 and a twelve month high of $35.02. The company has a 50-day moving average price of $26.66 and a 200-day moving average price of $21.50.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the prior year, the firm posted ($0.04) EPS. The business's quarterly revenue was up 77.1% compared to the same quarter last year. Equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total transaction of $68,932.24. Following the transaction, the insider now directly owns 184,947 shares of the company's stock, valued at $6,206,821.32. This trade represents a 1.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Oluyemi Okupe sold 269,739 shares of the business's stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $20.31, for a total transaction of $5,478,399.09. Following the sale, the chief financial officer now directly owns 145,763 shares of the company's stock, valued at $2,960,446.53. This represents a 64.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,064,514 shares of company stock worth $26,712,334 in the last 90 days. Corporate insiders own 17.71% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on HIMS shares. Deutsche Bank Aktiengesellschaft upped their price target on Hims & Hers Health from $23.00 to $27.00 and gave the stock a "hold" rating in a research report on Wednesday, November 6th. Needham & Company LLC raised their price target on Hims & Hers Health from $28.00 to $31.00 and gave the stock a "buy" rating in a report on Monday. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a "buy" rating in a report on Monday, December 2nd. Piper Sandler lifted their target price on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a "neutral" rating in a research note on Monday. Finally, Bank of America lowered shares of Hims & Hers Health from a "buy" rating to an "underperform" rating and cut their price target for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, Hims & Hers Health currently has a consensus rating of "Hold" and an average price target of $24.07.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.